Ginsenoside Rb1-engineered nanocomposite hydrogel promotes pressure injury repair through SIRT1-AMPK-mediated ferroptosis inhibition and angiogenesis activation
Journal of Ginseng Research · 2026-05 · 50 (3) · 100987
DOI: 10.1016/j.jgr.2026.100987 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Ginseng Research, 2026-05. Verfasst von Hongbo Zhu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Affiliated Hospital of Hebei University of Engineering, Handan, 056000, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Department of Health of Hebei Province.
Themen: Dekubitus
Abstract (Originalsprache)
Background
Pressure injuries (PIs) remain a therapeutic challenge due to persistent inflammation and ferroptosis-driven tissue damage. Ginsenoside Rb1, a key bioactive component of Panax ginseng, demonstrates anti-inflammatory and anti-ferroptotic properties, but its clinical application is limited by poor bioavailability and rapid degradation in wound environments.
Purpose
This study aimed to develop a chitosan/alginate nanocomposite hydrogel loaded with ginsenoside Rb1 (Rb1@CS@ALG) to enhance Rb1 delivery and investigate its therapeutic mechanisms in PI repair, focusing on SIRT1-AMPK-mediated ferroptosis inhibition and angiogenesis promotion.
Methods
The pH-responsive Rb1@CS@ALG hydrogel was synthesized and characterized (TEM/DLS/HPLC). In vitro studies evaluated ferroptosis markers (GPX4, SLC7A11), ROS levels, and cell migration in HaCaT cells under ischemia-reperfusion. A rat PI model (n = 6/group) assessed wound closure rates, histopathology (H&E/Masson's), and protein expression (CD31/Col I). RNA-seq analyzed differential gene expression.
Results
The hydrogel showed sustained Rb1 release (82.3 % at 24 h) and pH-dependent drug delivery. Treatment upregulated GPX4/SLC7A11 (2.3-fold) while reducing ROS (58 %) and ACSL4 (45 %) via SIRT1-AMPK activation (p-AMPK↑2.9-fold). In vivo, it accelerated wound closure by 75 % (vs. controls, p < 0.001), increased angiogenesis (CD31↑3.1-fold), and improved collagen organization (Col I/III ratio↑2.7-fold). RNA-seq confirmed enrichment in ferroptosis and extracellular matrix pathways.
Conclusion
This study establishes ginsenoside Rb1 as a potent therapeutic agent for PIs when delivered via nanocomposite hydrogel, with dual mechanisms of ferroptosis inhibition and angiogenesis activation. The findings provide a scientific foundation for applying ginseng-derived compounds in chronic wound management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Affiliated Hospital of Hebei University of Engineering, Handan, 056000, China.
- Procurement Office, Affiliated Hospital of Hebei University of Engineering, Handan, 056000, China.
Förderung
- Department of Health of Hebei Province
Zitieren
APA
Zhu, H., Li, H., Shi, Y., Liu, J., Zhi, H., Zhao, X., Wang, Z., & Ping, F. (2026). Ginsenoside Rb1-engineered nanocomposite hydrogel promotes pressure injury repair through SIRT1-AMPK-mediated ferroptosis inhibition and angiogenesis activation. Journal of Ginseng Research, 50(3), 100987. https://doi.org/10.1016/j.jgr.2026.100987
Vancouver
Zhu H, Li H, Shi Y, Liu J, Zhi H, Zhao X, et al. Ginsenoside Rb1-engineered nanocomposite hydrogel promotes pressure injury repair through SIRT1-AMPK-mediated ferroptosis inhibition and angiogenesis activation. Journal of Ginseng Research. 2026;50(3):100987. doi:10.1016/j.jgr.2026.100987
BibTeX
@article{Zhu2026,
author = {Zhu, Hongbo and Li, Hang and Shi, Yinong and Liu, Jinhui and Zhi, Hua and Zhao, Xuelu and Wang, Zhiwen and Ping, Fumin},
title = {Ginsenoside Rb1-engineered nanocomposite hydrogel promotes pressure injury repair through SIRT1-AMPK-mediated ferroptosis inhibition and angiogenesis activation},
journal = {Journal of Ginseng Research},
year = {2026},
volume = {50},
number = {3},
pages = {100987},
doi = {10.1016/j.jgr.2026.100987}
}
EUVIMED